Subscribe
Launches
4 min read

A supplement brand bets that cat compliance is a format problem, not a formula one

Pet Honesty launched Cat Squeezables, eight lickable purée supplements for cats, live on DTC, Amazon, and Chewy now and reaching Petco in August. The actives are commodity; the bet is that the lickable format cats already love solves the supplement-compliance problem that caps the category.

Written by
The Underbite
Published on
July 8, 2026
A supplement brand bets that cat compliance is a format problem, not a formula one

The hardest part of cat wellness has never been the science. It is getting a famously stubborn animal to swallow it. Pet Honesty's new Cat Squeezables line bets the fix is delivery, not chemistry: put functional supplements inside the lickable purée format cats already treat as a reward, and the compliance problem mostly solves itself.

Pet Honesty launches eight lickable supplement purées for cats

On July 7, Pet Honesty introduced Cat Squeezables, a line of eight lickable purées that each pair a targeted health formula with a format cats readily eat. The eight cover Calming Support, Digestive Gut Health, Hairball Support, Immune System Support, Daily Multivitamin, Senior Mobility Support, Skin & Coat Health, and Urinary Tract Health.

The purées are made with real salmon and omega-3s, grain free and high protein, without by-products or cellulose. The active ingredients are standard supplement fare matched to each benefit, including lysine, glucosamine, pre- and postbiotics, cranberry extract, psyllium husk, taurine, zinc, chamomile, L-theanine, and L-tryptophan.

Pet Honesty says it spent 18 months on feeding and palatability testing, and cites an independent feeding study in which 100% of cats consumed the product. The line is available now direct on PetHonesty.com, Amazon, and Chewy, with Petco retail distribution arriving in August.

Founded in Austin in 2018 and majority-owned by Vestar Capital Partners since 2021, Pet Honesty describes itself as the number-one and fastest-growing cat supplement portfolio brand in the U.S., a company claim it did not attribute to a measurement source. Its existing lines already sit in Walmart, Target, Petco, PetSmart, Pet Supplies Plus, and Tractor Supply.

Why format, not formula, is the real moat

Read the ingredient panel and nothing jumps out. Glucosamine, taurine, cranberry, L-tryptophan: these are commodity actives available in every supplement aisle. The wedge here is not what is inside the tube. It is the tube.

Lickable purées are the fastest-growing shape in cat treats, a category worth roughly $1.62 billion in 2024 and growing at about 7.5% a year, with purée the dominant format. Inaba's Churu built the behavior, training a generation of cats to mob the squeeze tube. Pet Honesty is grafting function onto that trained response.

The logic is sound because a supplement a cat refuses has an efficacy of zero, and cats refuse pills, powders, and most chews. Solve adherence and you solve the thing that actually caps this category. That is also why the "100% consumed" figure, small study caveats aside, is the metric that matters. In supplements, palatability is not a nice-to-have. It is the input to repeat purchase, subscription retention, and lifetime value.

The move collapses two categories into one contested space. Lickable-treat incumbents like Inaba and Hartz sell enjoyment with little function. Supplement brands like VetriScience and Zesty Paws sell function and fight compliance daily. Pet Honesty wants the overlap, and it is not alone for long. Expect functional purées from the supplement players and "wellness" line extensions from the treat incumbents within a couple of quarters, plus private label at Chewy and Amazon. The format itself is not defensible. Brand, shelf position, and velocity are.

The distribution sequence is the disciplined part. Leading with direct, Amazon, and Chewy lets Pet Honesty prove velocity online, where format novelty travels cheaply, before committing to Petco slotting fees in August. It is a controlled omni ramp, not a land grab.

What the August Petco rollout will test

Petco is the real exam. Direct-to-consumer and Amazon reward novelty, but a physical shelf forces a positioning choice: does Cat Squeezables live in the treat aisle next to Churu, or in the supplement set next to the chews? Each planogram implies a different buyer, a different price expectation, and a different competitor.

Watch price per tube against plain Churu. Function earns a premium, but purée shoppers anchor to treat pricing, and the spread between the two is the entire margin story. Watch, too, whether rivals ship their own functional purées before the holidays. If Zesty Paws or a private-label program moves quickly, the format edge compresses into a brand-and-distribution race, which is exactly the fight a Vestar-backed incumbent already stocked in six national chains wants to have.

The broader signal for operators is simple. In cat wellness, the growth lever is shifting from the ingredient list to the delivery format. The brands that win will pick the shape the animal already accepts and put the function inside it.

Source: Pet Honesty announcement via Business Wire.

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

What's Happening

Other News

More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.

Read article
Vetspire Splits From Thrive, Lands a Battery Ventures Backing
Funding & M&A
4 min read

Vetspire Splits From Thrive, Lands a Battery Ventures Backing

Vetspire has spun out of Thrive Pet Healthcare's orbit with a growth investment from Battery Ventures and a new CEO, Zachary Seely. The AI-powered practice management platform, used by more than 800 veterinary hospitals and clinics, will operate independently while Thrive remains a customer. The deal tests whether AI-native vet software can draw institutional capital without a strategic parent underwriting it.

Read article
Read article
PetMeds Revenue Falls 20% as Takeover Fight Drags On
Earnings
6 min read

PetMeds Revenue Falls 20% as Takeover Fight Drags On

PetMeds' first-quarter revenue fell 19.9% to $41.0 million and cash reserves dropped to $13.1 million, even as the company narrowed its net loss to $6.1 million from $34.2 million a year earlier. The results land as an unsolicited $3-a-share buyout offer from SilverCape Investments remains on the table and a $37 million sale-leaseback of its headquarters awaits closing.

Read article
Read article
FDA Clears Zoetis Drug for Screwworm as Outbreak Spreads North
Regulatory
4 min read

FDA Clears Zoetis Drug for Screwworm as Outbreak Spreads North

The FDA granted Zoetis an emergency use authorization for Simparica Trio to treat New World screwworm in dogs, the first product cleared specifically for the threat. Texas has already begun requiring treatment before dogs cross certain lines, putting boarding facilities, transporters, and border-state vet practices under a new compliance mandate.

Read article
View all articles